S-1/A: Pasithea Therapeutics Launches $60M Offering Amid Clinical Progress

Pasithea Therapeutics Corp. announced a public offering of up to $60 million in common stock and pre-funded warrants to fund its clinical-stage biotechnology programs, despite ongoing operating losses and Nasdaq compliance challenges.

Summary

• Pasithea Therapeutics Corp. is offering up to 75,000,000 shares of common stock and/or pre-funded warrants, with an assumed public offering price of $0.80 per share of common stock and $0.799 per pre-funded warrant.
• The offering aims to raise approximately $54.9 million in net proceeds, assuming all common stock is sold, which will be used for general corporate purposes including research and development, clinical trials, and potential acquisitions.
• The company is a clinical-stage biotechnology firm focused on CNS disorders, RASopathies, and MAPK pathway-driven tumors, with its lead candidate PAS-004 in Phase 1 trials for advanced tumors and NF1-PN.
• Recent clinical updates include completion of enrollment for cohort 6 in the FIH Phase 1 study, initiation of a Phase 1/1b trial for NF1-PN, activation of new clinical sites, and positive interim Phase 1 data for PAS-004.
• The ALS Association awarded a $1 million grant to study PAS-004 in ALS patients.
• Pasithea received a Nasdaq deficiency notice on June 23, 2025, for not meeting the $1.00 minimum bid price requirement, with a compliance deadline of December 22, 2025, and is considering a reverse stock split.
• The company has incurred significant net losses, with an accumulated deficit of approximately $59.9 million as of September 30, 2025, and its independent audit firm included a going concern explanatory paragraph for the year ended December 31, 2024.

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. While there is positive clinical trial progress and a significant capital raise, the company faces substantial financial challenges, including ongoing losses, a 'going concern' warning, and a Nasdaq delisting threat. The offering provides a necessary lifeline but does not resolve the underlying profitability issues or high operational burn rate.

Positives

• Positive interim Phase 1 data for PAS-004 in advanced solid tumors driven by MAPK pathway alterations was announced on November 20, 2025.
• Positive tablet PK data from the Phase 1/1b open-label study evaluating PAS-004 in adult NF1-PN patients was announced on November 21, 2025.
• Positive safety, PK, and PD data from Cohort 7 (37mg capsule) in the first-in-human trial for PAS-004 was announced on November 24, 2025.
• The ALS Association awarded a Hoffman ALS Clinical Trial Award grant worth approximately $1 million to study PAS-004 in ALS patients on November 25, 2025.
• The company successfully initiated a Phase 1/1b clinical trial for PAS-004 in adult NF1-PN patients on May 14, 2025, and has activated multiple clinical sites.
• Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing authorized shares for issuance by 1,750,000 to 2,014,221 shares on September 3, 2025.

Negatives

• The company has incurred losses since inception, with net losses of approximately $13.9 million for 2024 and $16.0 million for 2023, and an accumulated deficit of approximately $59.9 million as of September 30, 2025.
• Existing cash and cash equivalents of $4.1 million as of September 30, 2025, are only sufficient to fund operations through December 2025, prior to the proceeds from this offering.
• The independent registered public accounting firm's report for the fiscal year ended December 31, 2024, contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company received a Nasdaq deficiency notice on June 23, 2025, for not meeting the $1.00 minimum bid price requirement, with a compliance period until December 22, 2025, and faces potential delisting.
• This is a 'best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital for its business plans.
• New investors in this offering will experience immediate and substantial dilution of approximately $0.08 per share based on the assumed public offering price of $0.80 per share.

Risks

• The company has incurred losses since inception and anticipates continued losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• Significant additional capital will be required to fund operations, and failure to obtain necessary financing may prevent the completion of drug development and commercialization.
• The report of the independent registered public accounting firm for the fiscal year ended December 31, 2024, contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, which may affect financing and stock price.
• Management has broad discretion in the use of net proceeds from this offering, and ineffective application could materially adversely affect the business.
• Purchasers in this offering will experience immediate and substantial dilution in the net tangible book value of their shares.
• There is no public market for the Pre-Funded Warrants being offered, and their speculative nature means there is no assurance their market value will equal or exceed the public offering price.
• Failure to comply with Nasdaq continued listing requirements, specifically the $1.00 minimum bid price, may result in the common stock being delisted.
• A potential reverse stock split to regain Nasdaq compliance may not achieve the intended results and could negatively impact the market price of the common stock.
• Future sales of outstanding securities, including shares underlying existing warrants and those sold through the at-the-market offering facility, may cause the market price of the company's securities to drop significantly.
• The limited number of authorized and available shares of common stock may restrict the company's ability to raise future capital and execute its business strategy, potentially leading to more costly financing options or impacting Nasdaq listing requirements.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, including ongoing research and pre-clinical studies, clinical trials for its product candidates (PAS-004, PAS-003, PAS-001), development of new biological and pharmaceutical technologies, and potential investments in or acquisitions of synergistic companies. The FIH Phase 1 Dose Escalation Study for PAS-004 is expected to complete in 2026, and the company aims to conduct a Phase 1 trial for pediatric NF1-PN patients and ultimately complete registrational clinical trials in both adult and pediatric NF1-PN populations.

Management Comments

• Management will have broad discretion in the application of the net proceeds from this offering, relying on their judgment regarding the use of funds for corporate purposes, including R&D and potential acquisitions.
• The company is monitoring the closing bid price of its common stock and considering options, including a potential reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement.

Industry Context

Pasithea Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on CNS disorders and oncology. Its lead candidate, PAS-004, is a next-generation MEK inhibitor, a class of drugs with existing market players. The company's strategy involves advancing its pipeline through clinical trials and seeking regulatory approvals, a process characterized by high costs and uncertain outcomes. The grant from the ALS Association highlights the ongoing industry interest and investment in treatments for neurodegenerative diseases.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience immediate and substantial dilution from the offering. The capital raise provides funding for operations and clinical trials, which could lead to long-term value creation if successful, but the 'going concern' warning and Nasdaq delisting risk pose significant threats to investment value.
• **Employees:** The capital raise and continued R&D efforts provide stability and potential for continued employment and growth opportunities within the company's clinical programs.
• **Customers/Patients:** Continued funding for clinical trials, particularly for PAS-004 in advanced tumors and NF1-PN, offers hope for the development of new treatments for serious diseases.
• **Creditors:** The capital raise improves the company's liquidity and ability to meet its short-term obligations, potentially reducing immediate credit risk, but the 'going concern' issue remains a long-term concern.

Next Steps

• Complete the first-in-human (FIH) Phase 1 Dose Escalation Study for PAS-004 in patients with MAPK pathway-driven advanced tumors, expected in 2026.
• Conduct a Phase 1 trial for pediatric NF1-PN patients.
• Complete registrational clinical trials in both adult and pediatric NF1-PN populations for PAS-004.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by December 22, 2025, potentially through a reverse stock split.
• Utilize the net proceeds from the current offering for ongoing research and pre-clinical studies, clinical trials, and general corporate purposes.

Key Dates

Recommendation

Pasithea Therapeutics is at a critical juncture. The significant capital raise, if fully subscribed, provides a much-needed financial runway to advance its clinical programs, particularly PAS-004, which has shown positive interim data. The ALS Association grant further validates its research. However, the company's substantial accumulated deficit, ongoing operating losses, and the 'going concern' warning from its auditors indicate high financial risk. The Nasdaq minimum bid price deficiency and potential delisting add further uncertainty. While clinical progress offers long-term potential, the immediate financial and regulatory challenges warrant a 'hold' recommendation, advising investors to monitor the successful completion of the offering, progress in clinical trials, and resolution of the Nasdaq compliance issue before making further investment decisions.

Keywords

Biotechnology, Clinical-stage, Public Offering, Common Stock, Pre-Funded Warrants, PAS-004, MEK Inhibitor, MAPK Pathway, NF1, Plexiform Neurofibromas, ALS, Schizophrenia, Nasdaq Listing, Capital Raise, SEC Filing